Keyphrases
Acute Myeloid Leukemia
68%
MTOR Inhibitor
23%
Relapsed or Refractory
23%
Venetoclax
23%
Mammalian Target of Rapamycin (mTOR)
21%
Leukemic Cells
20%
Leukemia
20%
Granulocyte Colony-stimulating Factor (G-CSF)
20%
Plerixafor
19%
Kinase Inhibitor
19%
Acute Myeloid Leukemia Cells
18%
Chemotherapy
17%
Complete Remission
15%
Hematological Malignancies
15%
Anti-leukemia
15%
Leukemia Patients
14%
Induced Apoptosis
14%
Acute Lymphoblastic Leukemia
14%
Apoptosis
14%
Bone Marrow Microenvironment
14%
CXCR4 Inhibitor
13%
Stem Progenitor Cells
13%
Everolimus
13%
Phase II Study
13%
Busulfan
12%
C-X-C Chemokine Receptor Type 4 (CXCR4)
12%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
12%
Proteomic Profiling
12%
Fludarabine
12%
Philadelphia Chromosome
12%
Leukemia Cells
12%
Rapamycin
10%
Sorafenib
8%
Chemotherapy-induced
8%
Phosphorylation
8%
MTOR Complex 2 (mTORC2)
8%
Dose-limiting Toxicity
8%
Acute Leukemia
7%
Stromal Cell-derived factor-1 (SDF-1)
7%
Microenvironment
7%
FMS-like Tyrosine Kinase 3 (FLT3)
7%
Survival Signaling
7%
RAD001
7%
Remission
7%
Single Center
7%
Azacitidine
7%
Signaling Network
7%
Decitabine
7%
Mechanism of Action
7%
Leukemia Therapy
7%
Medicine and Dentistry
Acute Myeloid Leukemia
83%
Leukemia Cell
48%
Leukemia
41%
Programmed Cell Death
28%
Progenitor Cell
27%
Mammalian Target of Rapamycin Inhibitor
24%
Bone Marrow Microenvironment
23%
Phosphotransferase Inhibitor
19%
Acute Lymphoblastic Leukemia
19%
Stromal Cell
17%
Venetoclax
15%
Stroma
15%
Plerixafor
14%
Mass Cytometry
14%
Granulocyte Colony Stimulating Factor
13%
Philadelphia 1 Chromosome
13%
Allogeneic Stem Cell Transplantation
12%
Busulfan
12%
Fludarabine
12%
Proteomics
12%
In Vitro
11%
Drug Resistance
10%
Chronic Myelogenous Leukemia
10%
Tyrosine-Kinase Inhibitor
10%
Diseases
10%
Mechanistic Target of Rapamycin
9%
Acute B-Cell Lymphoblastic Leukemia
8%
B Cell
7%
Clinical Trial
7%
Mesenchymal Stem Cell
7%
Catenin
7%
Conditioning
7%
Stromal Cell Derived Factor 1
7%
Cytarabine
7%
Decitabine
6%
Protein Microarray
6%
Cell Signaling Pathway
6%
Gamma Chemokine
6%
Pyruvic Acid
6%
Chronic Leukemia
6%
Methyltransferase
6%
Blast Cell Crisis
6%
Acute Leukemia
6%
Bardoxolone Methyl
6%
Neutralizing Antibody
6%
Electron Transport
6%
Oxidative Phosphorylation Uncoupling
6%
2 (4 Amino 1 Isopropyl 1h pyrazolo[3,4 D]pyrimidin 3 Yl) 1h Indol 5 Ol
6%
Sapanisertib
6%
Everolimus
6%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Leukemia
53%
Chemotherapy
34%
Venetoclax
28%
Mammalian Target of Rapamycin Inhibitor
26%
Remission
26%
Acute Lymphoblastic Leukemia
21%
Granulocyte Colony Stimulating Factor
20%
Plerixafor
20%
Phosphotransferase Inhibitor
19%
Hematologic Malignancy
15%
Philadelphia 1 Chromosome
13%
Azacitidine
13%
Fludarabine
12%
Ivosidenib
12%
Busulfan
12%
Diseases
11%
Protein Tyrosine Kinase Inhibitor
10%
Chronic Myeloid Leukemia
10%
Mammalian Target of Rapamycin
9%
Stromal Cell Derived Factor 1
9%
Clinical Trial
8%
Sorafenib
8%
Tumor Growth
8%
Everolimus
8%
Phosphotransferase
8%
Catenin
7%
Tolerability
7%
Decitabine
6%
Myeloid Leukemia
6%
Rapamycin
6%
Gamma Chemokine
6%
Bardoxolone Methyl
6%
Phosphoprotein Phosphatase 2A
6%
Lymphatic Leukemia
6%
Chemokine Receptor
6%
Methyltransferase
6%
Phosphoinositide Dependent Protein Kinase 1
6%
Murine
6%
Phosphatidylinositol 3 Kinase Inhibitor
6%
microRNA
6%
STAT3 Protein
6%
Protein P53
6%
Triterpenoid
6%
Sapanisertib
6%
2 (4 Amino 1 Isopropyl 1h pyrazolo[3,4 D]pyrimidin 3 Yl) 1h Indol 5 Ol
6%
Monotherapy
6%
Janus Kinase
6%
Isocitrate Dehydrogenase 1
6%
Phase I Trials
6%